Document is current
Any future updates will be listed below
-
Authors
Eichinger, Anna https://orcid.org/0000-0002-2256-6633
Poetschger, Ulrike
Glogova, Evgenia
Bader, Peter https://orcid.org/0000-0003-4554-0265
Basu, Oliver
Beier, Rita
Burkhardt, Birgit https://orcid.org/0000-0002-1151-829X
Classen, Carl-Friedrich
Claviez, Alexander https://orcid.org/0000-0001-7064-8556
Corbacioglu, Selim
Deubzer, Hedwig E. https://orcid.org/0000-0002-6115-4893
Greil, Johann
Gruhn, Bernd https://orcid.org/0000-0003-1862-0075
Güngör, Tayfun https://orcid.org/0000-0002-3261-1186
Kafa, Kinan
Kühl, Jörn-Sven
Lang, Peter https://orcid.org/0000-0001-7737-2142
Lange, Bjoern Soenke
Meisel, Roland https://orcid.org/0000-0001-5230-0628
Müller, Ingo https://orcid.org/0000-0002-7477-6632
Sauer, Martin G.
Schlegel, Paul-Gerhardt
Schulz, Ansgar https://orcid.org/0000-0002-7798-7996
Stachel, Daniel
Strahm, Brigitte https://orcid.org/0000-0002-6086-130X
Wawer, Angela
Peters, Christina https://orcid.org/0000-0003-0369-8515
Albert, Michael H. https://orcid.org/0000-0001-9143-3263
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (EI 1185/1-1)
- License Information
-
More Information
Article History
Received: 20 July 2022
Revised: 25 August 2022
Accepted: 26 August 2022
First Online: 12 September 2022
Competing interests
: AC, AS, AW, BB, BG, BS, BSL, CFC, DS, EG, HD, IM, JG, KK, MS, OB, PGS, PL, RB, SC, TG and UP have no conflict of interest to declare. AE has received conference support from Gilead. JSK has a consulting/advisory role with Bluebird Bio and has received honoraria from Jazz Pharmaceuticals. PB declares research support from Neovii, Riemser and Medac, advisory role for Novartis, Cellgene, Amgen, Medac and Servier, speakers bureau for Miltenyi, Jazz, Riemser, Novartis, Amgen and holds a patent with and receives royalties from Medac. RM has a consulting/advisory role with Bluebird Bio, Vertex Pharmaceuticals, Bellicum Pharmaceuticals, Novartis and has received travel/accommodation support by Jazz Pharmaceuticals. CP received funding from Amgen, Neovii, Medac, Novartis, Pfizer, Jazz and Riemser. MHA has a consulting/advisory role with Orchard Therapeutics, Bluebird Bio, Bellicum Pharmaceuticals, CSL, Biotest and has received travel/accommodation support by octapharma, Medac, Neovii and Jazz Pharmaceuticals.
